CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Mitchell Shawnte CHIEF LEGAL OFFICER | Option exercise | +15,000 | $4.37 | $66K | 15,000 |
| 2026-03-03 | Mitchell Shawnte CHIEF LEGAL OFFICER | Sale | −15,000 | $23.01 | $345K | 0 |
| 2026-03-03 | Mitchell Shawnte CHIEF LEGAL OFFICER | Option exercise · Stock Option (Right to Buy) | −15,000 | 435,000 | ||
| 2026-02-02 | Austin Sasha Lu VP of Finance and Controller | Grant or award | +11,700 | 16,188 | ||
| 2026-02-02 | Austin Sasha Lu VP of Finance and Controller | Grant or award · Stock Option (Right to Buy) | +29,250 | 29,250 | ||
| 2026-02-02 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2026-02-02 | Zojwalla Naseem CHIEF MEDICAL OFFICER | Grant or award · Performance Stock Options (Right to Buy) | +106,250 | 106,250 | ||
| 2026-02-02 | Bohen Sean PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +850,000 | 850,000 | ||
| 2026-02-02 | Bohen Sean PRESIDENT AND CEO | Grant or award · Performance Stock Options (Right to Buy) | +275,000 | 275,000 | ||
| 2026-02-02 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2026-02-02 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Grant or award · Performance Stock Options (Right to Buy) | +106,250 | 106,250 | ||
| 2026-02-02 | Mitchell Shawnte CHIEF LEGAL OFFICER | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2026-02-02 | Mitchell Shawnte CHIEF LEGAL OFFICER | Grant or award · Performance Stock Options (Right to Buy) | +56,250 | 56,250 | ||
| 2026-01-20 | Harmon Cyrus Director | Sale | −10,000 | $26.88 | $269K | 727,770 |
| 2026-01-15 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Sale | −100,000 | $28.73 | $2.9M | 139,727 |
| 2026-01-14 | Harmon Cyrus Director | Sale | −3,489 | $29.12 | $102K | 737,770 |
| 2026-01-14 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | +50,000 | $4.87 | $244K | 592,761 |
| 2026-01-14 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −14,997 | $28.60 | $429K | 577,764 |
| 2026-01-14 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −35,003 | $28.99 | $1.0M | 542,761 |
| 2026-01-14 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Option exercise · Stock Option (Right to Buy) | −50,000 | 50,000 |
Page 2 of 11 · 207 trades